United Therapeutics Corporation (UTHR) Earnings Per Share (EPS): 27.05
Is United Therapeutics Corporation’s earnings per share (EPS) high or low?
United Therapeutics Corporation's earnings per share (EPS) of 27.05 is 40% above its 5-year average of 19.31, near the high end of its 5-year range (10.60–30.13).
As of Saturday, June 13, 2026. 4.37% below its 12-month average of 28.29.
UTHR Earnings Per Share (EPS) Chart
UTHR Average Earnings Per Share (EPS) Chart
UTHR Current vs Average Earnings Per Share (EPS) Chart
UTHR Earnings Per Share (EPS) Metrics
EARNINGS PER SHARE (EPS)
27.05
EARNINGS PER SHARE (EPS) AVG TTM
28.29
EARNINGS PER SHARE (EPS) AVG 3Y
23.40
EARNINGS PER SHARE (EPS) AVG 5Y
19.31
EARNINGS PER SHARE (EPS) AVG 10Y
15.18
EARNINGS PER SHARE (EPS) AVG 15Y
11.81
EARNINGS PER SHARE (EPS) AVG 20Y
9.14
CURRENT VS TTM AVG
-4.37%
CURRENT VS 3Y AVG
+15.61%
CURRENT VS 5Y AVG
+40.11%
CURRENT VS 10Y AVG
+78.23%
CURRENT VS 15Y AVG
+128.95%
CURRENT VS 20Y AVG
+195.87%
UTHR Competitors' Earnings Per Share (EPS)
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $23.17B | 27.05 | 28.29 | 23.40 | 19.31 |
| Waters Corporation (WAT) | $23.17B | 7.87 | 10.78 | 11.05 | 10.65 |
| BioNTech SE (BNTX) | $22.90B | -5.94 | -4.08 | 9.21 | 14.48 |
| Mettler-Toledo International Inc. (MTD) | $22.86B | 42.71 | 41.42 | 39.43 | 36.04 |
| Labcorp Holdings Inc. (LH) | $21.83B | 11.29 | 9.71 | 9.57 | 13.14 |
| Veeva Systems Inc. (VEEV) | $25.92B | 5.61 | 4.98 | 4.09 | 3.61 |
| Moderna, Inc. (MRNA) | $19.80B | -8.15 | -8.27 | -1.90 | 3.46 |
| DexCom, Inc. (DXCM) | $29.08B | 2.34 | 1.80 | 1.48 | 1.30 |
| Hologic, Inc. (HOLX) | $16.97B | 2.40 | 2.92 | 3.22 | 4.07 |
| Biogen Inc. (BIIB) | $29.53B | 9.34 | 10.02 | 12.26 | 14.06 |
EPS Comparison
Trailing EPS (TTM)
$27.05
Forward EPS (Est.)
$33.12
P/E Ratio
20.2
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
- Directly impacts stock valuation through P/E ratio
- Used to calculate dividend coverage and payout ratios
- Enables comparison across companies of different sizes
- Growth in EPS often correlates with stock price appreciation
United Therapeutics Corporation Earnings Per Share (EPS) Formula & Definition
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation Earnings Per Share (EPS) FAQ
- What is the earnings per share (EPS) for United Therapeutics Corporation (UTHR)?
- The earnings per share (EPS) for UTHR stock is 27.05.
- Is United Therapeutics Corporation's earnings per share (EPS) high or low?
- United Therapeutics Corporation's earnings per share (EPS) of 27.05 is 40% above its 5-year average of 19.31, near the high end of its 5-year range (10.60–30.13).
- What is the TTM average earnings per share (EPS) for United Therapeutics Corporation (UTHR)?
- The TTM average earnings per share (EPS) for UTHR stock is 28.29.
- What is the 3Y average earnings per share (EPS) for United Therapeutics Corporation (UTHR)?
- The 3Y average earnings per share (EPS) for UTHR stock is 23.40.
- What is the 5Y average earnings per share (EPS) for United Therapeutics Corporation (UTHR)?
- The 5Y average earnings per share (EPS) for UTHR stock is 19.31.
- What is the 10Y average earnings per share (EPS) for United Therapeutics Corporation (UTHR)?
- The 10Y average earnings per share (EPS) for UTHR stock is 15.18.
- What is the 15Y average earnings per share (EPS) for United Therapeutics Corporation (UTHR)?
- The 15Y average earnings per share (EPS) for UTHR stock is 11.81.
- What is the 20Y average earnings per share (EPS) for United Therapeutics Corporation (UTHR)?
- The 20Y average earnings per share (EPS) for UTHR stock is 9.14.
United Therapeutics Corporation Earnings Per Share (EPS) History
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 30.13 |
| 2024-12-31 | 26.44 |
| 2023-12-31 | 21.04 |
| 2022-12-31 | 15.98 |
| 2021-12-31 | 10.60 |
| 2020-12-31 | 11.65 |
| 2019-12-31 | -2.39 |
| 2018-12-31 | 13.54 |
| 2017-12-31 | 9.50 |
| 2016-12-31 | 16.29 |
| 2015-12-31 | 14.17 |
| 2014-12-31 | 7.06 |
| 2013-12-31 | 3.49 |
| 2012-12-31 | 5.84 |
| 2011-12-31 | 3.81 |
| 2010-12-31 | 1.89 |
| 2009-12-31 | 0.37 |
| 2008-12-31 | -0.93 |
| 2007-12-31 | 0.47 |
| 2006-12-31 | 1.61 |
| 2005-12-31 | 1.43 |
| 2004-12-31 | 0.36 |
| 2003-12-31 | -0.24 |
| 2002-12-31 | -0.57 |
| 2001-12-31 | -0.92 |
| 2000-12-31 | -1.97 |
| 1999-12-31 | -1.26 |
| 1998-12-31 | -0.77 |
Related Metrics
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt